Incyte registers two Phase 1 PK studies of INCB161734, in renal and hepatic impairment
New trial listings cover participants with severe kidney disease or on hemodialysis, and separately those with liver impairment, both not yet recruiting.
Incyte added two new registry entries this week, both early-stage pharmacokinetics studies of the same investigational drug.
- INCB161734 is being tested in a Phase 1 open-label trial (sponsor ID INCB161734-106) enrolling participants with severe renal impairment or end-stage renal disease based on CKD-EPI criteria1. The study is not yet recruiting, with an estimated start date of 2026-10-261, and plans to enroll an estimated 24 participants1, with INCB161734 given as a single oral dose1.
- A separate Phase 1 open-label study (sponsor ID INCB161734-105) is testing the same drug in participants with moderate or severe hepatic impairment based on Child-Pugh score2. The trial is not yet recruiting, with an estimated start date of 2026-10-132, and also targets an estimated enrollment of 24 participants2.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.